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(9.51.0); standing (8.41.8); sleep (7.92.3); work-related activities (7.92.4); walk-
ing (7.82.2); sexual activity (7.71.7); emotions (7.72.4); lifting (7.62.5); sitting
(7.52.0); social activities (7.22.4); and traveling (6.82.2). CONCLUSIONS: Quali-
tative interviews identified a wide-variety of bothersome symptoms and impacts
experienced by patients with cLBP. Patient-reported outcome instruments should
measure those experiences, which reflect concepts most relevant to patients. Ad-
ditional work is needed to assess whether items measuring these concepts are
sensitive to change with treatment.
PSY36
CHANGES IN PAIN INTENSITY AND HEALTH RELATED QUALITY OF LIFE (QOL)
IN PATIENTS WITH PERIPHERAL NEUROPATHIC PAIN AFTER A SINGLE
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OBJECTIVES: The primary objective was to examine the effect of 8% capsaicin
patch on change in “usual pain” using a PNRS (Pain Numeric Rating Scale) from
baseline to end of treatment. A secondary objective was to examine utility scores
assessed by the EQ-5D. METHODS: Adult patients (n211) diagnosed with periph-
eral neuropathic pain (excluding diabetes polyneuropathy) were included. The fol-
lowing parameters were investigated over a 12 week follow up period after a single
application: - Pain Numeric Rating Scale (PNRS, 0-10) to assess average pain inten-
sity over the last 24 hours, i.e., “usual pain” - EQ-5D - Size of treated area. RESULTS:
A total of 196 patients completed the study, 66% women and 34% men. Mean age
was 54.2 years (range 18-87). At baseline, the “usual pain” intensity was 6.3 (SD 1.8).
The mean change of PNRS from baseline to 14 - 90 days post treatment (average
pain reduction) was -0.90 (SD 2.08), p  0.001. Maximum mean reduction of “usual
pain” at any time point was -1.77 (SD 2.36), p 0.001. Mean EQ-5D health score was
0.29 (SD 0.31) at baseline (range -0.38-1.00). During the post-treatment period the
change was 0.26 (SD 0.30), p  0.001. At baseline, 66% of all patients reported
“Extreme Problem” in the pain/discomfort dimension and corresponding figures
for the post-treatment period was 43%. Median area treated was estimated to 179
cm2(range 3-1120) corresponding to 1.3 patches used per patient per treatment.
CONCLUSIONS: In this population of patients with peripheral neuropathic pain
and a markedly reduced QoL, a single treatment of capsaicin 8% significantly re-
duced patients’ experience of “usual pain” and improved short-term QoL evaluated
by EQ-5D.
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OBJECTIVES: Review the development and properties of PRO instruments used in
clinical trials and observational studies of patients with SLE. METHODS: A struc-
tured search was conducted to identify published articles in 2005-2011 through key
literature databases (EMBASE and MEDLINE/PUBMED). Conference abstracts from
targeted rheumatology, outcomes research and quality-of-life (QOL) scientific
meetings in 2009-2011 were included. SLE therapy clinical trials within the past five
years were identified through the ClinicalTrials.gov database. RESULTS: Over 60
different PRO instruments were used in SLE-related research; 7 were lupus specific,
11 assessed general QoL and the rest assessed select (diverse) disease symptoms
(e.g., fatigue, pain) or other patient attributes (e.g., satisfaction, adherence). The
SF-36, LupusQoL, and LupusPRO were most frequently used in SLE research. These
instruments have 36, 34, and 43 items, respectively. All three instruments have a
recall period of past four weeks; they demonstrated robust reliability and construct
validity when used in SLE patient samples, but generally weak associations
(r0.12-0.29) with SLE disease-activity indices. Validated symptom-specific FACIT-
Fatigue scale was also used in some studies to measure this important aspect of
patient experience and it correlated with SLE disease-activity indices. Recently, 10
items from the LupusPRO were validated for use as ‘Lupus Impact Tracker’ (LIT) to
retain the reliability and validity of the longer tool while decreasing questionnaire
burden. Brief validated instruments used in rheumatic-diseases (e.g., RAPID3: 15
items) are also being studied in SLE. CONCLUSIONS: The SF-36, LupusQoL, and
LupusPRO are the most widely used validated PRO instruments, but these have a
varying degree of questionnaire burden and specificity to SLE symptoms. Shorter
versions of validated PROs (e.g., SF-12, LIT) or instruments such as RAPID3 may
minimize questionnaire burden. The practicality of these PRO instruments for use
in daily practice to discriminate clinically meaningful changes in patient-reported
SLE treatment outcomes deserves further investigation.
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OBJECTIVES: To identify symptoms and impacts associated with chronic low back
pain (cLBP) that patients report spontaneously and in response to probes during
concept elicitation interviews.METHODS:Adult patients (18-80 years) with clinical
diagnosis of cLBP of non-malignant origin present for at least 3 months with a
current pain score 4 on a 0-10 numerical rating scale (NRS) were recruited from
U.S. and Germany sites. In order to explore relevance of concepts to patients,
trained qualitative interviewers conducted semi-structured individual interviews,
using open-ended questions to elicit spontaneous reports of symptom/impact con-
cepts, followed by probe questions to assure full coverage of concept domains.
Transcripts were coded using Atlas.ti and summarized by distinct concepts. Inter-
view guide notations were used to tag each concept offered by spontaneous versus
probed report. RESULTS: Forty-three patient interviews were conducted (mean
age: 48.613.0, 53.5% female, 74.4% -White/Caucasian). Mean (SD) pain NRS score
was 6.7(1.3). Spontaneously reported symptoms included: Numbness (51.2% of sub-
jects), Burning (39.5%), and Pain that was Shooting (37.2%), Stabbing (37.2%), and
Sharp (37.2%). The low back pain symptoms reported most often in response to
probes included Stiffness (55.8% of subjects), Excruciating Pain (41.9%), Pressure
(39.5%), Cramping (32.6%), and Pins and Needles (30.2%). Spontaneously reported
impacts included interference with: Walking (65.1%), Sitting (62.8%), Exercise
(58.1%), Leisure Activities (58.1%), Sleeping (55.8%), Household Chores (53.5%), and
Emotional Impacts (48.8%). Impacts reported most often in response to probes
included Low Energy because of pain (67.4%), Productivity (65.1%), Financial Impact
(46.5%), Driving (39.5%), and Relationships (37.2%). CONCLUSIONS: Given the vari-
ety of symptoms and impacts described by patients as part of their cLBP experi-
ence, those reported spontaneously may be more relevant to patients compared to
those reported upon probes. Characterizing patient reported concepts by sponta-
neous and probed may be useful in increasing the overall sensitivity of the patient
reported outcome assessment tool to detect change.
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OBJECTIVES: Evaluate the reliability and validity of the LIT, a 10-item PRO assess-
ment of the impact of SLE on the patient’s life. Additionally, the acceptability and
feasibility of LIT from the patient’s and physician’s perspectives was assessed.
METHODS: Baseline data were collected on 325 SLE patients during a clinic visit.
Patients completed the LIT, SF-36v2, LupusQoL, and PHQ-9. Both patients and phy-
sicians completed a questionnaire on the feasibility/acceptability of LIT. Patients
completed the LIT 7-14 days following baseline to assess test-retest reliability.
Physicians completed disease activity assessments (SELENA-SLEDAI, BILAG, and
SLICC/ACR Damage Index), a physician’s global assessment (PGA) and patient’s
recent flare status. Reliability was evaluated using internal consistency methods
(Cronbach’s alpha) and test-retest methods (intra-class correlation). Convergent
validity was evaluated by correlating LIT scores with scale scores from the SF-36v2,
LupusQoL, and PHQ-9. Construct validity was evaluated by comparing mean LIT
scores across patients that differed in PGA ratings and presence/absence of a recent
flare. ANOVA and Student’s t-tests were used to test mean differences in LIT scores
across patient groups. It was hypothesized that LIT scores would be lower among
patients with lower PGA ratings and no recent flare. RESULTS: Internal consistency
and test–retest reliabilities of LIT were 0.90 and 0.88, respectively. Convergent va-
lidity correlations ranged from -0.63 to -0.75 with SF-36v2 scales, from -0.42 to -0.75
with LupusQoL scales, and 0.75 with the PHQ-9. Mean LIT scores differed as hy-
pothesized across patients with different PGA ratings (F5.8, df2, p0.004). Mean
LIT scores differed between patients with and without a recent SLE Flare (t2.11,
p0.038). The majority (70%) of both patients and physicians found LIT to be
acceptable and feasible to administer in a clinic setting. CONCLUSIONS: The LIT is
a reliable and valid instrument for assessing the impact of SLE on patient’s func-
tioning and well-being.
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OBJECTIVES: Scarce data is available on the economic burden associated with
haemophilia B (HB). The aim of this study was to evaluate in a representative
French HB population the impact on health-related quality of life (HRQOL) and to
estimate the costs associated with its management. METHODS: EQOFIX is a pro-
spective cohort study in patients with moderate and severe HB with one year
follow-up. Data collected included: patients’ demographic and clinical character-
istics, severity status, therapeutical approach, FIX consumption and all other re-
sources used. Two types of HRQOL were used: generic (Kidscreen for children and
SF-36 for adults) and specific (QUAL-HEMO, specific to haemophilia patients). The
French national health insurance perspective was considered to estimate the av-
erage annual cost using official cost database. RESULTS:A total of 155 patients had
been included by 27 centres, representing a coverage rate of 25% of the French
global population suffering from severe and moderate HB: 104 adults (74 severe and
30 moderate) and 51 children (40 severe and 11 moderate). 30.4% of patients re-
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ceived preventive treatment; 60.4% were on-demand treatment. Severe HB adults
reported significantly poorer HRQOL than the moderate subgroup mainly on phys-
ical components. No HRQOL difference was observed among children. The average
annual direct cost was €95,619 (SD 83,142) with no significant difference between
adults and children, but with a difference with severity status (3.3 times higher in
severe vs. moderate HB, p0.001). Substitutive therapy represented 90%, of the
total followed by hospitalizations 6.5%. Even if the prophylaxis strategy lead to
higher costs than an on-demand strategy (p0.001), it allows avoiding haemor-
rhagic events and remains in acceptable cost-effectiveness range. CONCLUSIONS:
To date, no economic burden of disease studies focusing only on HB have been
published. The EQOFIX study provides an important source of economic informa-
tion for health care payers.
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OBJECTIVES: The purpose of this study was to characterise the subjective experi-
ence of anaemic patients with CKD and specifically to identify a set of the most
salient symptoms and impacts associated with anaemia and iron supplementa-
tion, both in pre-dialysis and dialysis patients. METHODS: This was a cross-sec-
tional, semi-qualitative study in which one-on-one concept elicitation interviews
were conducted among CKD subjects treated with iron supplementation, alone or
in conjunction with erythropoiesis-stimulating agents (ESAs). The interviews were
audiotaped and transcribed for thematic content analysis. RESULTS: A total of 40
participants were included with median age 53 (range: 27-83 years) and 55% male.
Twenty-two of the participants were on dialysis and of those nearly all received
intravenous iron (91%) and ESAs (91%). Conversely, the majority of pre-dialysis
patients instead used oral iron (72%) while ESA use was less common (44%) in this
segment. Fatigue was the most frequently reported symptom related to anaemia
(83%). Other common symptoms included shortness of breath and itchiness. The
defining symptoms related to iron supplementation were gastrointestinal in na-
ture (abdominal pain, constipation, flatulence, bloating, nausea and vomiting).
These symptoms negatively affected mood and social activities (28%). A difference
between oral and intravenous iron was that the degree of bothersomeness from
nausea and gastrointestinal side effects was more pronounced in those receiving
iron tablets. Iron supplementation was specifically mentioned by some patients to
cause nausea and vomiting and thus interfering with keeping medication down. As
a result, iron supplementation side effects were severe enough to negatively affect
medication compliance. CONCLUSIONS: The results from this study highlight the
great burden anaemia of CKD can have on quality of life, social life and emotional
well-being. Alternative treatments that avoid the side effects of iron supplemen-
tation have the potential to substantially improve quality of life in this patient
population.
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OBJECTIVES:An observational study to investigate effectiveness and safety of anti-
TNF agents in treatment of moderate-to-severe psoriasis vulgaris was conducted in
25 centres from Turkey. This sub-analysis aimed to evaluate the results of work
productivity and activity impairment. METHODS: Patients (18 years) were fol-
lowed-up 24 weeks (visits at 4, 8, 16 and 24 week after baseline) and psoriasis area
and severity index (PASI), dermatology life quality index (DLQI) and work produc-
tivity and activity impairment (WPAI) questionnaires were completed. RESULTS:A
total of 86 patients (38.4% females, mean(standard deviation) age 42.8(13.5) years,
mean(SD) body mass index 29.5(16.2) kg/m2) with psoriasis vulgaris for mean(SD)
16.4 (8.7) years were included to the study. Of patients; 18.6%, 17.4% and 17.4% were
dyslipidemic, hypertensive and hyperglycaemic, respectively. Unemployment rate
among patients was 59% at baseline. The employed patients reported a median
(interquartile-range) 11(44)% absenteeism rate, 50(40)% presenteeism rate and
57(57)% work productivity loss at baseline and those decreased to median(IQR)
0(0)%, 0(20)% and 0(20)% at week 24, respectively (P0.001, P0.001 and P0.001,
respectively). Among all patients, median(IQR) activity impairment rate decreased
to 5(30)% at week 24 from 60(50)% at baseline (P0.001). Baseline median(IQR) PASI
score was 20(15) and decreased to 2(4) at week 24, whereas baseline median(IQR)
DLQI score was 16(10) and decreased to 1.5(7) at week 24 (P for both 0.001). The
reduction in PASI showed a moderate positive linear correlation with absenteeism,
presenteeism, work productivity and loss activity impairment rate (Rhos 0.47,
0.48, 0.45, 0.49, respectively, for all P0.05). CONCLUSIONS: Moderate-to-severe
psoriasis vulgaris seemed to cause high absenteeism, presenteeism, work produc-
tivity and loss activity impairment rates and anti-TNF agents significantly im-
proved work productivity and activity impairment. Anti-TNF agents also signifi-
cantly reduced PASI and DLQI scores and reduction in PASI was moderately
correlated with work productivity and activity impairment.
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UTILIZATION OF PAIN MEDICATIONS IN PATIENTS WITH CHRONIC LOWER
BACK PAIN WHO INITIATED DULOXETINE OR STANDARD OF CARE FOR THE
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OBJECTIVES: To describe pain medication use in patients with chronic lower back
pain (CLBP) after initiating duloxetine or standard of care (SOC) for pain
management. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult patients with CLBP who initiated duloxetine or SOC (muscle
relaxants, gabapentin, pregabalin, venlafaxine, and tricyclic antidepressants) be-
tween 11/2010 and 4/2011. Treatment initiation was defined as no pill coverage for
duloxetine or SOC in previous 90 day. Included patients had no opioid use in 90
days before initiation. Propensity score matching was used to select patients with
similar baseline demographic and clinical characteristics for duloxetine and SOC
cohorts. Compliance to index medication was assessed via medication possession
ratio (MPR) and proportion of days covered (PDC) for 6 months after initiation.
Proportion receiving opioids and days on opioids after index date were assessed
and regression models were estimated to compare opioid use between cohorts.
RESULTS: 766 patients initiated duloxetine and 6,206 patients initiated SOC. After
matching, 743 patients were selected for the duloxetine (mean age: 57 years; fe-
male: 74%) and SOC (mean age: 57 years; female: 75%) cohorts, respectively. 92% of
duloxetine cohort started on or below recommended daily dose (60mg). Dulox-
etine cohort had significantly higher MPR (0.78 vs. 0.60) and PDC (0.50 vs. 0.31), were
less likely to use opioids (45% vs. 61%), and had fewer days on opioids (mean: 18 vs.
25) than SOC cohort (all p0.001). After adjusting for demographic and clinical
characteristics, duloxetine cohort initiated opioids later than SOC cohort (hazard
ratio: 0.76, 95% confidence interval: 0.65-0.88), and had fewer days on opioids (-6.9,
p0.001). CONCLUSIONS: CLBP patients initiating duloxetine had better compli-
ance to initiated medication and were less likely to use opioids than those initiating
SOC.
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OBJECTIVES: To evaluate the cost effectiveness of azacitidine treatment in com-
parison with Conventional Care Regimens (CCR), available in Greece. The analysis
is based on a National Health Service perspective.METHODS:A Markov model was
explored based on the Phase III randomized trial AZA-001, where patients were
analyzed over their lifetime. The health outcomes were estimated on:i) life years
(LY) gained and ii) Quality Adjusted Life Years (QALYs) gained. The cost outcomes
were the average direct costs associated with each MDS treatment arm (relating to
drugs and medications, monitoring, routine follow-up and adverse event manage-
ment). The cost effectiveness of azacitidine treatment, compared to BSC, LDC, and
SDC treatments, was based on the Incremental Cost Effectiveness Ratio (ICER). The
model was customized into the Greek Health Care Setting by launching a struc-
tured questionnaire addressed to Greek hematologists from 6 Hospitals. They pro-
vide information on the resource use for the management of blood product trans-
fusions and adverse events complications in Greece. RESULTS: The incremental
cost of treating the patients with azacitidine, compared to treating them with BSC
was €94,585. The incremental life years gained for azacitidine compared to BSC
were 2.63. The resulting incremental cost effectiveness ratio (cost per life year
gained) was €35,909 when comparing azacitidine with BSC. Equivalently, the ICER
of treating patients with azacitidine as compared with treating them with LDC or
SDC was €29,708 and €27,074 respectively. With regard to QALYs azacitidine is also
effective resulting in an additional 1.65 QALYs gained compared to BSC, 1.8 QALYs
compared to LDC, and 1.81 QALYs compared to SDC. .The corresponding ICERs
were €57,158, €47,791and €47,651 versus, BCD, LDC and SDC, respectively.
CONCLUSIONS: Azacitidine is a cost effective option for the treatment of Greek
MDS patients generating significant improvements in quality-adjusted survival.
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OBJECTIVES: The BURQOL-RD project is intended to develop a disease based model
capable of quantifying the socio-economic burden and Health-Related Quality of
Life (HRQOL) for patients with rare diseases (RD) and their caregivers in Europe.
Preliminary results from Spain are presented here. METHODS: On-line survey of
patients and carers afected by Cystic Fibrosis, Prader-Willi Syndrome, Haemo-
philia, Duchenne Muscular Dystrophy, Epidermolysis Bullosa, Fragile X Syndrome,
Sclerodermia, Mucopolysaccharidosis, Juvenile Idiopathic Arthritis or Histiocytosis
was launched in Spain through national patients organizations in September 2011
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